Rhizen Pharmaceuticals AG

Abbmira therapeutics is a Basel based biotech founded by experience scientists and entrepreneurs in September 2024. Abbmira develops first-in-class small molecules to fine-tune native immunity to treat difficult-to-treat cancers and chronic diseases.

Discover if your new anti-cancer drug will work! Our validated platform uses intact patients tumors, maintains their complexity and cellular component, and overcomes organoids. This allows to reliably assess at the pre-clinical stage the efficacy of drugs in patients.